Amendments to the Claims

1, (Previously Presented) A compound of formula I:

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is $-C(R^{4c}) = \text{ or } -N =$:

R¹ is mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo, C₁-C₂ alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R2 is hydrogen or methyl;

R3 is hydrogen;

R4a and R4b are hydrogen

When X is -C(R4c)=, R4c is hydrogen

R5 is hydrogen; and

R⁶ is hydrogen.

- 2. -8 (Cancelled)
- (Currently Amended) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutical carrier, diluent, or excipient.
 - 10. 13 (Cancelled)
- 14. (Currently Amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:

Serial No. 10/552,131

or a pharmaceutically acceptable acid addition salt thereof, where;

O is oxygen or sulfur;

X is $-C(R^{4c})= or -N=;$

R¹ mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo, C₁-C₂ alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R2 is hydrogen or methyl;

R3 is hydrogen;

R4a and R4b are hydrogen;

When X is $-C(R^{4c})=$, R^{4c} is hydrogen;

R5 is hydrogen; and

R6 is hydrogen

15. (Original) The method according to Claim 14 wherein the mammal is a human.

16.- 28 (Cancelled)

29. (Previously Presented) A compound of formula I:

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is -C(H)= or -N=:

R¹ is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R2 is hydrogen or methyl;

Serial No. 10/552.131

R3 is hydrogen;

R4a and R4b are hydrogen

R5 is hydrogen; and

R6 is hydrogen.

- (Currently Amended) A pharmaceutical composition comprising a compound according to Claim 29 and a pharmaceutical carrier, diluents, or excipient.
- 31. (Currently Amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I;

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is -C(H)= or -N=;

 R^1 is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R2 is hydrogen or methyl;

R3 is hydrogen:

R4a and R4b are hydrogen

R5 is hydrogen; and

R6 is hydrogen.

32. (Previously Presented) The method according to Claim 31 wherein the mammal is human.

4